Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Vor Biopharma Inc (VOR)

78 + Investors. Track Smart Money conviction in VOR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +23
Streak
3Q ▲
Buyers last Q
74%

Smart Money Signals — VOR

Based on 78 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added VOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
78 hedge funds hold VOR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +77% more funds vs a year ago

fund count last 6Q
+34 new funds entered over the past year (+77% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 3 quarters from the low — a sharp move.
🟢

More buyers than sellers — 74% buying

62 buying22 selling
Last quarter: 62 funds were net buyers (36 opened a brand new position + 26 added to an existing one). Only 22 were sellers (9 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+11 vs last Q)

new funds entering per quarter
Funds opening a new VOR position: 10 → 13 → 25 → 36. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
📌

Mixed — 33% long-term, 51% new

■ 33% conviction (2yr+) ■ 15% medium ■ 51% new
Of the 78 current holders: 26 (33%) held >2 years, 12 held 1–2 years, and 40 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +105% but shares only +50% — price-driven

Value
+105%
Shares
+50%
Last quarter: the total dollar value of institutional holdings rose +105%, but actual share count only changed +50%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

10 → 10 → 13 → 25 → 36 new funds/Q
New funds entering each quarter: 10 → 13 → 25 → 36. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 49% veterans vs 43% newcomers

■ 49% veterans ■ 8% 1-2yr ■ 43% new
Entry-cohort mix of 79 holders: 39 (49%) are 2+ year veterans, 6 entered 1–2 years ago, and 34 (43%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 12% AUM from top-100

12% from top-100 AUM funds
21 of 78 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
5.6
out of 10
Moderate Exit Risk
Exit risk score 5.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — VOR

In 2026 Q1, 62 hedge funds were net buyers of VOR (36 opened a new position, 26 added to an existing one), while 22 reduced or exited (9 trimmed, 13 sold completely) — a 74% buyer ratio, indicating clear institutional accumulation. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. Net fund flow last quarter: +23 funds (more new holders than closures). Total institutional holders: 78.

Hedge Fund Ownership: VOR

How many hedge funds hold VOR — quarterly history vs. share price
Quarterly hedge fund ownership of VOR vs. share price

Market Analysis: VOR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: VOR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Vor Biopharma Inc (VOR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much VOR has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 80d ago
VOR
nan%
XLV
+2.1%

VOR outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 35d ago
VOR
nan%
XLV
+3.2%

Since the filing became public, VOR outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

10 top-rated funds 8 high-conviction
Consensus
4.5
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: VOR
78 + Investors

Track Smart Money conviction in VOR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 78 55 41.82%
13F Shares 41M 27M 50.06%
Total Value $719M $350M 105.25%
New Positions 36 25 +11
Increased Positions 23 19 +4
Closed Positions 13 10 +3
Reduced Positions 9 5 +4
Total Calls 0 5 -100.0%
Total Puts 1 3 -66.67%
PUT/CALL Ratio 0.0 0.6 Bullish

Statistics: VOR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

78 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VOR. Verified SEC 13F-HR filings.

QUARTER:
Top 25 VOR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Fcpm III Services B.V. 10.17% 4,117,354 $73.5M
2 NEXTBio Capital Management LP 8.28% 999,967 $17.8M
3 Great Point Partners LLC 7.18% 1,750,000 $31.2M
4 Rosalind Advisors, Inc. 5.02% 700,000 $12.5M
5 Propel Bio Management, LLC 3.52% 314,543 $5.6M
6 TCG Crossover Management, LLC 2.76% 5,673,078 $96.5M
7 Caligan Partners LP 2.29% 1,925,066 $34.3M
8 Venrock Adviser, LLC 2.03% 3,041,719 $54.3M
9 Frazier Life Sciences Management, L.P. 1.17% 2,543,939 $45.4M
10 Ra Capital Management, L.P. 1.02% 5,404,998 $96.4M
11 Sphera Funds Management LTD. 0.91% 321,917 $5.7M
12 Logos Global Management LP 0.67% 750,000 $13.4M
13 Paradigm Biocapital Advisors LP 0.64% 1,750,000 $31.2M
14 Cannon Global Investment Management, LLC 0.41% 11,700 $209K
15 Clearline Capital LP 0.30% 326,168 $5.8M
16 Sarissa Capital Management LP 0.29% 25,399 $453K
17 Braidwell LP 0.28% 466,774 $8.3M
18 Laurion Capital Management LP 0.25% 318,670 $5.7M
19 Scientech Research LLC 0.22% 15,047 $268K
20 Johnson & Johnson 0.15% 53,732 $959K
21 Boothbay Fund Management, LLC 0.13% 555,702 $9.9M
22 Diametric Capital, LP 0.05% 10,070 $180K
23 Jump Financial, LLC 0.04% 173,028 $3.1M
24 Irenic Capital Management LP 0.04% 32,663 $583K
25 Axq Capital, LP 0.03% 15,019 $268K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Vor Biopharma Inc (VOR)

What does the Smart Money Trend signal show for VOR?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added VOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for VOR?

More buyers than sellers — 74% buying: Last quarter: 62 funds were net buyers (36 opened a brand new position + 26 added to an existing one). Only 22 were sellers (9 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for VOR holders?

Smaller funds dominant — 12% AUM from top-100: 21 of 78 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held VOR?

Mixed — 33% long-term, 51% new: Of the 78 current holders: 26 (33%) held >2 years, 12 held 1–2 years, and 40 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Vor Biopharma Inc (VOR) following the 2026 Q1 hedge fund 13F filings?

As of today, VOR has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), VOR has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →